Global Partners LP is experiencing a strong revenue acceleration, with Q2 2026 revenue up 46.8% year-over-year to $6.8B, driven by broad-based momentum. However, structurally thin gross margins (4.8% in Q2 2026) and high leverage (debt-to-equity of 2.68) sugge...
Price trend, volume and key moving averages
Trailing total returns as of 9/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 7, 2026 | $1.86+50.0% vs $1.24 | $6.8B-9.5% vs $7.5B |
Q2 2026 May 8, 2026 | $1.85+460.6% vs $0.33 | $5.3B-23.7% vs $7.0B |
Q1 2026 Feb 27, 2026 | $0.54-10.0% vs $0.60 | $4.6B-33.0% vs $6.9B |
Q4 2025 Nov 7, 2025 | $0.66-39.4% vs $1.09 | $4.7B-32.3% vs $6.9B |
Eli Lilly CEO Dave Ricks told CNBC on Monday that 700,000 new seniors have started GLP-1 treatments since Medicare coverage of obesity drugs launched in July. In an exclusive interview, Ricks said 70% of those patients are on Lilly medicines.
Eli Lilly CEO tells CNBC one-third of new GLP-1 pill patients are taking Foundayo, as drugmaker ramps up production
WW International NASDAQ: WW executives outlined the company's efforts to reposition its weight-management business around behavioral support, telehealth and GLP-1 medications, following a restructuring that substantially reduced its debt burden.
Kailera Therapeutics, Inc. targets the high-potential GLP-1 obesity market, leveraging a $718M IPO and a robust pipeline licensed from Hengrui. KLRA's lead candidate, ribupatide, shows competitive mean weight loss (23.6% at 36 weeks) and a favorable safety profile in ex-China studies. Despite a 40% post-IPO share price drop, KLRA's $1.65 bn valuation appears attractive given its late-stage pipeline and $900m cash balance.
Benchmark GLP against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Global Partners LP (GLP)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $48.18 | $1.64B | 22.83 | 8.14% | 0.43% | 11.38% | 7.68% | |
| $21.93 | $836.72M | 20.12 | -10.63% | 1.36% | — | — | |
| $2.22 | $86.67M | -5.99 | 1.2% | -1.48% | — | — | |
| $15.94 | $1.99B | -4.57 | -9.02% | -4.83% | -14.66% | — | |
| $75.06 | $10.27B | 20.51 | 11.05% | 2.81% | 14.72% | — | |
| $106.14 | $19.13B | 34.13 | -5.99% | 6.13% | 19.73% | — |
Global Partners LP (GLP) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Global Partners LP (GLP) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 7, 2026·SEC
Jul 30, 2026·SEC
Jul 29, 2026·SEC
Get notified when GLP posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Global Partners LP (GLP) stock FAQ — growth, dividends, profitability & financials explained
Global Partners LP (GLP) reported $21.46B in revenue for fiscal year 2025. This represents a 1124% increase from $1.75B in 2001.
Global Partners LP (GLP) grew revenue by 8.1% over the past year. This is steady growth.
Yes, Global Partners LP (GLP) is profitable, generating $172.4M in net income for fiscal year 2025 (0.4% net margin).
Yes, Global Partners LP (GLP) pays a dividend with a yield of 7.68%. This makes it attractive for income-focused investors.
Global Partners LP (GLP) has a return on equity (ROE) of 11.4%. This is reasonable for most industries.
Global Partners LP (GLP) generated $199.4M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
